Literature DB >> 16314854

Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.

Akira Takahara1, Atsushi Sugiyama, Yuko Ishida, Yoshioki Satoh, Kai Wang, Yuji Nakamura, Keitaro Hashimoto.   

Abstract

Although a second-generation histamine H(1) blocker terfenadine induced torsades de pointes (TdP) arrhythmias in patients via the blockade of a rapid component of delayed rectifier K(+) current (I(Kr)), such action of terfenadine has not been detected in previous animal models. We analysed the potential of the canine persistent atrioventricular block heart, a new in vivo proarrhythmia model, to detect a torsadogenic effect of terfenadine of an oral dose of 3 or 30 mg kg(-1). The doses can provide therapeutic to supra-therapeutic plasma concentrations as an anti-histamine. In 2 weeks of bradycardiac heart model, there were no significant changes in any of the electrocardiogram parameters after the administration of both doses of terfenadine. In 4-6 weeks of bradycardiac heart model, the low dose of terfenadine hardly affected any of the electrocardiogram parameters except that it induced TdP in one out of six animals. The high dose significantly decreased the atrial rate and ventricular rate, prolonged the QT interval, and induced TdP in five out of six animals. Moreover, temporal variability of repolarization increased after the high-dose administration. These results suggest that long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect terfenadine-induced TdP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16314854      PMCID: PMC1751346          DOI: 10.1038/sj.bjp.0706493

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Effects of a typical I(Kr) channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes.

Authors:  Atsushi Sugiyama; Keitaro Hashimoto
Journal:  Jpn J Pharmacol       Date:  2002-04

2.  Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.

Authors:  Lars Eckardt; Günter Breithardt; Wilhelm Haverkamp
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

Review 3.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Authors:  W S Redfern; L Carlsson; A S Davis; W G Lynch; I MacKenzie; S Palethorpe; P K S Siegl; I Strang; A T Sullivan; R Wallis; A J Camm; T G Hammond
Journal:  Cardiovasc Res       Date:  2003-04-01       Impact factor: 10.787

4.  Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.

Authors:  Andrew J Batey; Susan J Coker
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve.

Authors:  Péter Biliczki; László Virág; Norbert Iost; Julius Gy Papp; András Varró
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 6.  Assessing predictors of drug-induced torsade de pointes.

Authors:  Luiz Belardinelli; Charles Antzelevitch; Marc A Vos
Journal:  Trends Pharmacol Sci       Date:  2003-12       Impact factor: 14.819

7.  Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models.

Authors:  Atsushi Sugiyama; Yoshioki Satoh; Hiroyuki Shiina; Satoshi Takeda; Keitaro Hashimoto
Journal:  J Cardiovasc Pharmacol       Date:  2002-08       Impact factor: 3.105

8.  Electrophysiological safety of sertindole in dogs with normal and remodeled hearts.

Authors:  Morten B Thomsen; Paul G A Volders; Milan Stengl; Roel L H M G Spätjens; Jet D M Beekman; Ulrike Bischoff; Morten A Kall; Kristen Frederiksen; Jørgen Matz; Marc A Vos
Journal:  J Pharmacol Exp Ther       Date:  2003-09-09       Impact factor: 4.030

9.  Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability.

Authors:  Luc M Hondeghem; Peter Hoffmann
Journal:  J Cardiovasc Pharmacol       Date:  2003-01       Impact factor: 3.105

10.  Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog.

Authors:  Marieke Schoenmakers; Christian Ramakers; Jurren M van Opstal; Jet D M Leunissen; Camila Londoño; Marc A Vos
Journal:  Cardiovasc Res       Date:  2003-08-01       Impact factor: 10.787

View more
  8 in total

Review 1.  Cardiac GPCRs: GPCR signaling in healthy and failing hearts.

Authors:  Natasha C Salazar; Juhsien Chen; Howard A Rockman
Journal:  Biochim Biophys Acta       Date:  2007-02-20

2.  The anaesthetized rabbit with acute atrioventricular block provides a new model for detecting drug-induced Torsade de Pointes.

Authors:  Mihoko Hagiwara; Seiji Shibuta; Kazuhiro Takada; Ryuichi Kambayashi; Misako Nakajo; Megumi Aimoto; Yoshinobu Nagasawa; Akira Takahara
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

3.  No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.

Authors:  M B Thomsen; J D M Beekman; N J M Attevelt; A Takahara; A Sugiyama; K Chiba; M A Vos
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

4.  International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.

Authors:  A S Bass; B Darpo; A Breidenbach; K Bruse; H S Feldman; D Garnes; T Hammond; W Haverkamp; C January; J Koerner; C Lawrence; D Leishman; D Roden; J P Valentin; M A Vos; Y-Y Zhou; T Karluss; P Sager
Journal:  Br J Pharmacol       Date:  2008-08       Impact factor: 8.739

5.  Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.

Authors:  A Takahara; Y Nakamura; H Wagatsuma; S Aritomi; A Nakayama; Y Satoh; Y Akie; A Sugiyama
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 6.  Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.

Authors:  M A Vos
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 7.  Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.

Authors:  A Sugiyama
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

Review 8.  The canine chronic atrioventricular block model in cardiovascular preclinical drug research.

Authors:  Vera Loen; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2021-05-04       Impact factor: 9.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.